Dare Bioscience resumed with a Buy at Roth Capital

Roth Capital analyst Kumaraguru Raja resumed coverage of Dare Bioscience (DARE) with a Buy rating and $5 price target. The analyst notes that XACIATO for treatment of bacterial vaginosis is licensed to Organon for commercialization following FDA approval; Sildenafil Cream for female sexual arousal disorder and Ovaprene for contraception are in advanced stages of clinical development; and Dare has a license agreement with Bayer (BAYRY) for the commercialization of Ovaprene in the U.S. Raja believes that the risk-reward is favorable and clinical success would enhance interest in the company.